secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001193125-23-005674
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal reports supportive MAESTRO-NASH consensus read; NASH resolution and fibrosis improvement remain significant
--------------------------------------------------------------------------------

- Consensus read: NASH resolution 24% (80mg) and 28% (100mg) vs 8% placebo (p<0.0001).
- Fibrosis improvement ≥1 stage: 24% (80mg) and 26% (100mg) vs 12% placebo (p<0.0001).
- Analysis used digitized biopsies when two pathologists' scores disagreed on primary endpoints.
- Results consistent with primary analysis announced Dec 19, 2022; trial continues for up to 54 months.
- Data presented at NASH-TAG Conference on Jan 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523005674/0001193125-23-005674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523005674/d436279d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-005674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer